Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

RNAC stock hub

Cartesian Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RNACis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

254.2M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

RNAC

In the news

Latest news · RNAC

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROICn/a

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RNAC market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

185

Groups with data

Currency

USD

Showing 185 of 185 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001453687
Company name	Cartesian Therapeutics, Inc.
Country	United States
Country code	US
Cusip	816212302
Employees	75
Employees Change	9%
Employees Change Percent	13.64
Enterprise value	$147.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2016-06-22
Isin	US8162123025
Last refreshed	2026-05-10
Market cap	$254.2M
Market cap category	Micro-Cap
Price	$8.65
Price currency	USD
Rev Per Employee	23,666.67x
Sector	Healthcare
Sic	2834
Symbol	RNAC
Website	https://www.cartesiantherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-59.72%
EV Sales Forward	524.26x
EV/Sales	83.02x
FCF yield	-30.44%
P/S ratio	143.18x
PS Forward	904.15x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-61M
Net Income	$-151.8M
Net Income Growth Years	0%
Pretax Margin	-9,068.56%
Profit Per Employee	$-2M
ROA	-16.36
ROCE	-33.52

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-14.79%
EPS Growth Years	0
Revenue Growth	-94.81x
Revenue Growth Q	-92.91x
Revenue Growth Years	0x
Revenue Growth3 Y	-72.47x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.01
Assets	$288.4M
Cash	$118.6M
Current Assets	$122M
Current Liabilities	$15.9M
Debt	$11.9M
Equity	$-148.1M
Liabilities	$436.5M
Long Term Assets	$166.4M
Long Term Liabilities	$420.6M
Net Cash	$106.8M
Net Cash By Market Cap	$42.02
Net Cash Growth	-35.81%
Tangible Book Value	$-290.2M
Tangible Book Value Per Share	$-10.17
WACC	7.03

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	7.65
Net Working Capital	$-8.4M
Quick ratio	7.46
Working Capital	$106.1M
Working Capital Turnover	$0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-17.02%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-14.78%
200-day SMA	8.28
50-day SMA	6.89
50-day SMA vs 200-day SMA	50under200
All Time High	42.6
All Time High Change	-79.69%
All Time High Date	2023-11-27
All Time Low	5.6
All Time Low Change	54.46%
All Time Low Date	2026-03-27
ATR	0.55
Beta	0.56
Beta1y	1.89
Beta2y	2.25
Ch YTD	19.97
High	8.69
High52	15.57
High52 Date	2025-07-09
High52ch	-44.44%
Low	8.16
Low52	5.6
Low52 Date	2026-03-27
Low52ch	54.46%
Ma50ch	25.49%
Price vs 200-day SMA	4.52%
RSI	69.54
RSI Monthly	35.97
RSI Weekly	55.22
Sharpe ratio	0.15x
Sortino ratio	0.34
Total Return	-17.02%
Tr YTD	19.97
Tr1m	37.74%
Tr1w	39.07%
Tr3m	33.28%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	5
Analyst Price Target Top	$34
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.73
Earnings Revenue Estimate	205,912x
Earnings Revenue Estimate Growth	-81.28x
Operating Income	$-91.3M
Operating margin	-5,144.5
Price target	$34
Price Target Change	$293
Price Target Change Top	$293

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	9,601,107%
Float Percent	32.68%
Shares Insiders	54.93%
Shares Institutions	17.13%
Shares Out	29,381,514
Shares Qo Q	3.26%
Shares Yo Y	17.02%
Short Float	23.06%
Short Ratio	14.3
Short Shares	7.54

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-87.8M
Average Volume	198,590.4x
Bv Per Share	-5.19
CAPEX	$-4.4M
Ch1m	37.74
Ch1w	39.07
Ch1y	-14.78
Ch3m	33.28
Ch6m	9.91
Change	6%
Change From Open	5.36
Close	8.16
Days Gap	0.61
Depreciation Amortization	2,418,000
Dollar Volume	1,489,651.1
Earnings Date	2026-04-30
Earnings Time	bmo
EBIT	$-91.3M
EBITDA	$-88.9M
EPS	$-5.79
F Score	1
FCF	$-77.4M
FCF EV Yield	-52.51x
FCF Per Share	$-2.63
Financing CF	15,641,000
Fiscal Year End	December
Founded	2,007
Goodwill	48,163,000
Income Tax	$-9.2M
Investing CF	-4,406,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Last Split Date	2024-04-05
Last Split Type	Reverse
Last10k Filing Date	2026-03-09
Ma150	7.42
Ma150ch	16.55%
Ma20	6.92
Ma20ch	24.98%
Net CF	-61,727,000
Next Earnings Date	2026-08-06
Open	8.21
Optionable	Yes
Position In Range	92.45
Post Close	8.65
Postmarket Change Percent	-1.85
Postmarket Price	$8.49
Ppne	17,003,000
Price Date	2026-05-08
Relative Volume	0.87x
Revenue	1,775,000x
SBC By Revenue	587.94x
Share Based Comp	10,436,000
Tax By Revenue	-517.92x
Tr6m	9.91%
Us State	Maryland
Volume	172,214
Z Score	-4.45

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does RNAC pay a dividend?

Capital-return profile for this ticker.

Performance

RNAC stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns RNAC?

Insider, institutional, and short-interest positioning.

Institutional ownership

+17.1%

Float: +32.7% of shares outstanding

Insider ownership

+54.9%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RNAC momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

69.5

Neutral momentum band

Price vs 200-day MA

+4.5%

50/200-day relationship not available

Beta (5Y)

0.56

Less volatile than the market

Sharpe ratio

0.15

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RNAC

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RNAC stock rating?

Cartesian Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RNAC analysis?

The full report lives at /stocks/RNAC/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RNAC?

The latest report frames RNAC around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RNAC page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.